Nicholas B Figura, Wendy Long, Michael Yu, Timothy J Robinson, Sepideh Mokhtari, Arnold B Etame, Nam D Tran, Roberto Diaz, Hatem Soliman, Heather S Han, Solmaz Sahebjam, Peter A Forsyth, Kamran A Ahmed
PURPOSE: Leptomeningeal disease is a rare and devastating presentation of advanced stage metastatic breast cancer with historically poor overall survival. We assessed the safety and feasibility of intrathecal (IT) trastuzumab in HER2+ leptomeningeal disease. METHODS: A total of 13 patients were treated at our institution with IT trastuzumab beginning November 2012 and followed until November 2017. Outcomes including craniospinal progression as well as overall survival (OS) following initiation of IT trastuzumab were assessed from review of the clinical chart and radiologic examinations...
June 2018: Breast Cancer Research and Treatment